JPWO2020047530A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047530A5 JPWO2020047530A5 JP2021511591A JP2021511591A JPWO2020047530A5 JP WO2020047530 A5 JPWO2020047530 A5 JP WO2020047530A5 JP 2021511591 A JP2021511591 A JP 2021511591A JP 2021511591 A JP2021511591 A JP 2021511591A JP WO2020047530 A5 JPWO2020047530 A5 JP WO2020047530A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dosage range
- taurinamide
- taurultam
- once daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 21
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 claims 20
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical compound NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 claims 16
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 claims 15
- 229950007343 taurultam Drugs 0.000 claims 15
- 235000019256 formaldehyde Nutrition 0.000 claims 10
- 230000003442 weekly effect Effects 0.000 claims 10
- 239000002105 nanoparticle Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000000174 oncolytic effect Effects 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 claims 4
- 229960004267 taurolidine Drugs 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000002028 premature Effects 0.000 claims 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims 1
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 108700024542 myc Genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025088837A JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725650P | 2018-08-31 | 2018-08-31 | |
| US62/725,650 | 2018-08-31 | ||
| PCT/US2019/049266 WO2020047530A1 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088837A Division JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535167A JP2021535167A (ja) | 2021-12-16 |
| JPWO2020047530A5 true JPWO2020047530A5 (https=) | 2022-09-07 |
| JP2021535167A5 JP2021535167A5 (https=) | 2022-09-07 |
Family
ID=69643283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511591A Pending JP2021535167A (ja) | 2018-08-31 | 2019-09-03 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
| JP2025088837A Pending JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088837A Pending JP2025128194A (ja) | 2018-08-31 | 2025-05-28 | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3843747A4 (https=) |
| JP (2) | JP2021535167A (https=) |
| KR (1) | KR20210054544A (https=) |
| CN (1) | CN113226325A (https=) |
| AU (1) | AU2019331913B2 (https=) |
| CA (1) | CA3111100A1 (https=) |
| WO (1) | WO2020047530A1 (https=) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
| US7151099B2 (en) * | 1998-07-31 | 2006-12-19 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases |
| GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| CN100519525C (zh) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
| JP5027369B2 (ja) * | 1999-12-06 | 2012-09-19 | ガイストリッヒ ファーマ アーゲー | 腫瘍を治療する方法 |
| US20080171738A1 (en) * | 2001-04-03 | 2008-07-17 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of Breast Cancer |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| CA2482687C (en) * | 2003-09-29 | 2012-11-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
| US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| WO2007020509A1 (en) * | 2005-08-15 | 2007-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
| ES2377206T3 (es) * | 2006-01-06 | 2012-03-23 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam |
| CN103118669B (zh) * | 2010-06-01 | 2016-01-13 | 盖斯特里希医药公司 | 口服药物治疗方法和组合物 |
| EP3402527B1 (en) * | 2016-01-11 | 2022-09-28 | CorMedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
| CA3018145C (en) * | 2016-03-18 | 2024-09-17 | Geistlich Pharma Ag | TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER |
| JP2021535163A (ja) * | 2018-08-28 | 2021-12-16 | コーメディクス・インコーポレーテッド | タウロリジン加水分解産物による神経芽細胞腫治療 |
-
2019
- 2019-09-03 CN CN201980072806.2A patent/CN113226325A/zh active Pending
- 2019-09-03 EP EP19854097.3A patent/EP3843747A4/en active Pending
- 2019-09-03 CA CA3111100A patent/CA3111100A1/en active Pending
- 2019-09-03 JP JP2021511591A patent/JP2021535167A/ja active Pending
- 2019-09-03 AU AU2019331913A patent/AU2019331913B2/en active Active
- 2019-09-03 WO PCT/US2019/049266 patent/WO2020047530A1/en not_active Ceased
- 2019-09-03 KR KR1020217009412A patent/KR20210054544A/ko active Pending
-
2025
- 2025-05-28 JP JP2025088837A patent/JP2025128194A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system | |
| JP2024102099A5 (https=) | ||
| Wu et al. | Nanoparticle-based combination therapy for ovarian cancer | |
| US20210030680A1 (en) | Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer | |
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| JPH0710773B2 (ja) | 一定の放出性及び即時放出性を有する薬物粒子 | |
| WO2003039436A3 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| US11779644B2 (en) | Sensitizing cells to proton radiation | |
| JP2021535163A5 (https=) | ||
| Subramani et al. | A Novel Approach on Role of Polymers Used in Sustained Re-lease Drug Delivery System—A Review | |
| JPH0710772B2 (ja) | 一定の放出性を保持した薬物粒子 | |
| ES2922284T3 (es) | Uso de una dieta que simula el ayuno para mejorar la eficacia de los antiestrógenos en terapia contra el cáncer | |
| CN111658778A (zh) | 药物组合物及其制备方法与应用 | |
| JPWO2020047530A5 (https=) | ||
| JPWO2020047113A5 (https=) | ||
| Zhang et al. | Co-delivery of sorafenib and metformin from amphiphilic polypeptide-based micelles for colon cancer treatment | |
| Begg et al. | Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors | |
| JP2021535167A5 (https=) | ||
| JP5843086B2 (ja) | 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用 | |
| Paldor et al. | Targeted local therapy for management of intracranial high-grade gliomas | |
| JPWO2020247421A5 (https=) | ||
| Yehia et al. | Advanced biodegradable-based formulations for the treatment of arthritis | |
| US12053478B2 (en) | Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies | |
| JP2025128194A (ja) | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 | |
| US20240122918A1 (en) | NanoMesh Drug Delivery for Treatment of Brain Tumors |